Sime Armoyan Sells 300,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 300,000 shares of Knight Therapeutics stock in a transaction on Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00.

Knight Therapeutics Stock Down 1.8 %

TSE GUD traded down C$0.11 during trading hours on Friday, hitting C$6.02. The company had a trading volume of 31,200 shares, compared to its average volume of 66,414. The firm’s 50 day moving average is C$5.72 and its 200 day moving average is C$5.69. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. Knight Therapeutics Inc. has a fifty-two week low of C$4.35 and a fifty-two week high of C$6.23. The company has a market capitalization of C$609.28 million, a price-to-earnings ratio of -30.10, a P/E/G ratio of -1,013.50 and a beta of 0.48.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, August 8th. The company reported C($0.02) earnings per share for the quarter, missing the consensus estimate of C$0.03 by C($0.05). Knight Therapeutics had a negative return on equity of 2.70% and a negative net margin of 6.28%. The company had revenue of C$95.57 million during the quarter, compared to analysts’ expectations of C$89.83 million. Sell-side analysts anticipate that Knight Therapeutics Inc. will post 0.1077501 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GUD has been the topic of several research reports. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the stock from C$5.75 to C$6.75 in a research report on Tuesday, August 13th. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.